spacer
home > ebr > spring 2002 > canada - the number one country for conducting biomedical r&d
PUBLICATIONS
European Biopharmaceutical Review

Canada - The Number One Country for Conducting Biomedical R&D

While lower cost is a compelling reason for conducting R&D in Canada, it is just one of several. Other factors include:

Canada is home to one of the largest, most developed biotech sectors in the world

The potential for partnerships with biotech firms undertaking cutting edge R&D exists throughout Canada

Government funding and tax credits for R&D is generous

Regulations are science-based and conducive to commercialising new products

Social and demographic features make Canada an excellent place to conduct clinical trials

Market-size is enormous, since Canada as a member of the North American Free Trade Agreement (NAFTA) has increased access to both the US and Mexican marketplace


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Michael Rappaport, Publications Supervisor at BIOTECanada Michael Rappaport is the Editor of BIOTECanada Insights, a bilingual, biannual magazine designed to promote the Canadian biotech sector, and BIOTECanada Monthly Reporter, an industry newsletter that provides updates on government relations activities and communications initiatives. Before assuming the position of Publications Supervisor at BIOTECanada, Michael was a Science Writer for the Natural Science and Engineering Research Council, the main funding body for biological, chemical, physical and engineering sciences in Canada. He has a BA Honours degree in English Literature and Political Science, and a Master of Journalism from Carleton University in Ottawa.
spacer
Michael Rappaport
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Specialized expertise that gives you an inside edge

Tap into the knowledge of specialists with decades of experience identifying and solving difficult challenges. From technical obstacles such as siliconization and lyophilization to strategic issues such as life cycle planning, Vetterís integrated team approach brings together the right experts for your compoundís precise requirements.
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement